Faeth Therapeutics, Inc.
FTH · XNASCIK 1829802fmd_0270CWKJ2NRXRAM95KP344S6YGManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total operating expenses | 19 | 37 | 50 | 37 | 33 | 22 |
| Operating income | (19) | (37) | (50) | (37) | (33) | (22) |
| Interest expense | 2 | 1 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | – | (0) | 0 | (0) | (0) | (0) |
| Income before taxes | – | – | – | – | (30) | (21) |
| Income tax expense | – | – | – | – | 0 | 0 |
| Net income from continuing operations | – | – | – | – | (30) | (21) |
| Net income | (20) | (37) | (49) | (34) | (30) | (21) |
| Net income to common shareholders | (20) | (37) | (49) | (34) | (30) | (21) |